Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 13.41M P/E - EPS this Y 28.90% Ern Qtrly Grth -
Income -18.38M Forward P/E -0.92 EPS next Y 24.80% 50D Avg Chg -26.00%
Sales 79.57k PEG - EPS past 5Y - 200D Avg Chg -33.00%
Dividend N/A Price/Book 0.52 EPS next 5Y - 52W High Chg -65.00%
Recommedations 2.00 Quick Ratio 2.14 Shares Outstanding 7.46M 52W Low Chg 5.00%
Insider Own 12.02% ROA -76.21% Shares Float 5.98M Beta 1.33
Inst Own 14.35% ROE -149.69% Shares Shorted/Prior 39.66K/54.80K Price 2.53
Gross Margin - Profit Margin - Avg. Volume 23,838 Target Price 11.50
Oper. Margin -23,885.05% Earnings Date Nov 12 Volume 9,095 Change -2.32%
About Inhibikase Therapeutics, Inc.

Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.

Inhibikase Therapeutics, Inc. News
11/14/24 Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity
05:31 AM Inhibikase Therapeutics Secures Funding and Strengthens Leadership
10/22/24 Perceptive Advisors LLC Acquires New Stake in Inhibikase Therapeutics Inc
10/21/24 Inhibikase Therapeutics Announces Closing of up to $275 Million Financing and Advancement of IkT-001Pro into a Late Stage Clinical Trial in Pulmonary Arterial Hypertension
10/18/24 Fairmount Funds Management LLC Acquires New Stake in Inhibikase Therapeutics Inc
10/11/24 Inhibikase Therapeutics Secures $110M for Drug Development
10/11/24 Steven Cohen's Strategic Acquisition of Inhibikase Therapeutics Shares
10/10/24 Inhibikase Therapeutics Unveils PAH and Parkinson’s Drug Pipeline
10/09/24 Inhibikase Therapeutics Prices $110 Million Private Placement; Shares Jump
10/09/24 Inhibikase Therapeutics Announces Pricing of $110 Million Private Placement to Advance IkT-001Pro, an Optimized Prodrug of Imatinib, into a Late-Stage Trial in Pulmonary Arterial Hypertension
08/14/24 Inhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period Activity
08/07/24 Inhibikase Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024
06/17/24 Inhibikase Therapeutics Completes Enrollment of the Phase 2 ‘201’ Trial Evaluating Risvodetinib in Untreated Parkinson’s Disease
06/05/24 Inhibikase Therapeutics Announces Expansion to its Therapeutic Pipeline and Updates its Research and Development Programs
05/21/24 Inhibikase Therapeutics First Quarter 2024 Earnings: US$0.73 loss per share (vs US$0.98 loss in 1Q 2023)
05/20/24 Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $4.0 Million
05/15/24 Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity
05/15/24 Inhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration Statement
05/09/24 Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial Hypertension
04/18/24 Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs
IKT Chatroom

User Image Manbearpig2097 Posted - 1 day ago

$IKT I’m in

User Image QuizNose Posted - 1 day ago

$IKT this is just hilarious — data must be close

User Image BiotechJedi1728 Posted - 1 day ago

$IKT Run my child. Your time has come.

User Image QuizNose Posted - 1 day ago

$IKT oh, so they’re starting to let this trend up again… ok lol

User Image HuntingBenjmins Posted - 1 day ago

$IKT DANGIT! Missed that $1.75. I’m guessing a good bounce from here.

User Image jemer Posted - 1 day ago

$IKT https://www.biospace.com/deals/novartis-ceo-promises-more-deals-of-up-to-5b-with-an-eye-for-early-science

User Image jemer Posted - 2 days ago

$IKT 11 Healthcare institutions which now own 55MM shares could buy up the 4MM outstanding shares in a heartbeat, if they so wished. Surprised that an entity is manipulating IKT's share price recently. Seems awfully dangerous to me. Also, don't see Werner releasing Parkinsons results on a Friday or on a holiday week. My bet is 1st week of December, especially if results are positive.

User Image BiotechJedi1728 Posted - 2 days ago

$IKT Bought more at 1.95. Just missed 1.85. Shot up before I could snatch that bottom. Pretty happy with my share count now. This thing pops to $10-$20 on PD news. Enough for a down-payment on a car if I sell half. 🤞🏼 not a Lambo. Just something for my kid to drive.

User Image G101SPM Posted - 2 days ago

$IKT $1.85 bid. BUY/2X ADD TO LONG POSITION carries improved SPM on improved probability "... to advance IkT-001Pro into a late-stage clinical trial in Pulmonary Arterial Hypertension (PAH),” said Dr. Milton Werner, President and Chief Executive of Inhibikase. “This investment, with top tier dedicated healthcare investment funds, recognized the potential of IkT-001Pro to improve the lives of patients afflicted with PAH. We believe IkT-001Pro, a prodrug of imatinib, has the potential to ameliorate the safety and tolerability profile that precluded approval of imatinib for the treatment of PAH more than 10 years ago. This investment further validates the Company’s innovative approach to the development of kinase inhibitor therapeutics in the non-oncology setting." DAC (dollar average cost) (4) $1.985. EXIT $6.00 (near term as first tier).

User Image jemer Posted - 2 days ago

$IKT "Participant experience in the trial appears to be positive, as clinician and patient impression of disease status or severity is not changing over the 12 week course of dosing." Milton Werner March 7, 2024

User Image Texastea666 Posted - 2 days ago

@BiotechJedi1728 I don't know why you think $IKT is an automatic Parkinson win?

User Image penny_bagz Posted - 2 days ago

$IKT picked up more probably bad idea catching this falling knife. Be back next week for another 100

User Image BiotechJedi1728 Posted - 2 days ago

$IKT How long til Parkinson's announcement? Early next week? Who is selling now? Oh. Manipulators. MM's. Really a coin flip to double down here. I believe in the science. I don't believe in WallSt. morons and greedy fxcks.

User Image HuntingBenjmins Posted - 3 days ago

$IKT Dirty dog shorts…We had a good support at $1.92. They cracked it.

User Image El_Tropical Posted - 4 days ago

$IKT Increase authorized shares to 500m? WTF?

User Image Stttttt Posted - 4 days ago

$ADGM $DRUG $ENSC $IKT when ? $AZI is moving better then this

User Image Timmyturner22 Posted - 4 days ago

$ADGM Double bottom. Re-break over $3.00 will start the next leg. Extreme high chance this stock sees a LARGE price target upgrade in the near future. Most likely the people who filed the 13G will pay analysts. This stock is so light, when they decide to send it, it will move dollars fast $DRUG $ENSC $IKT

User Image biospeculator Posted - 4 days ago

$IKT Two filings yesterday may account for recent pps weakness. GLTA

User Image GuruChartist Posted - 6 days ago

$IKT Is the trend broken?

User Image BigPlaySnipers Posted - 1 week ago

$ADGM Look at this weekly Mac-d + the massive 13g and tiny float. This can go big $ENSC $ATHA $DRUG $IKT

User Image jemer Posted - 1 week ago

$IKT Armistice is a nasty predatory hedge fund. Werner has been forced to take their offering $$$ in the past and Armistice has not been a "friend" to IKT. They pump up share price and sell their shares and then short against their warrants. Wouldn't surprise me if Armistice is manipulating share price down in anticipation of positive Parkinsons data. With 93% of shares now held by partnering institutions, anybody shorting IKT is playing with fire!

User Image HuntingBenjmins Posted - 1 week ago

$IKT When you see a 50% haircut to recent highs it makes you think that the big boys are privy to information we are not. SMH

User Image HuntingBenjmins Posted - 1 week ago

$IKT Wasn’t expecting it to actually get worst than yesterday!

User Image wat92098 Posted - 1 week ago

$IKT buying all the way down

User Image kneehighnigel Posted - 1 week ago

$IKT is the trial news delayed. I only ever remember seeing (from $IKT ) "4th quarter 2024". I commented on here that midnight 31 December 2024 wouldn't be late. But somehow a legend has built around November. What was the source?

User Image biospeculator Posted - 1 week ago

$IKT With special thanks to TJC and his post of the fireside chat with Milton Werner and Maxim we can imo conclude he knows the unblinded results of the phase II study for PD. So why an apparent delay. IMO, always follow the money. If the results are good then he states every intention to raise capital for phase III. The phase IIb trial for PAH he believes is fully funded with the first raise. So why wait? Jan 3 special meeting in order to raise capital and maybe more important to grant additional shares to himself. For me I view this as a positive and will be a buyer during any additional weakness. JFK Jr is nothing but smoke or a buying opportunity for myself. We all remember Hillary's claims years ago and bought weakness and made $$$$. Also the recent buy rating now given twice is a clue. Companies never want to screw the analysts or investment banks they rely on. GLTA

User Image wat92098 Posted - 1 week ago

Inhibikase Therapeutics’ $IKT Promising Developments and Financial Backing Justify Buy Rating - TipRanks.com https://www.tipranks.com/news/blurbs/inhibikase-therapeutics-promising-developments-and-financial-backing-justify-buy-rating

User Image Texastea666 Posted - 1 week ago

$IKT https://x.com/i/status/1857169180832752007

User Image Paper_Route_Frank Posted - 1 week ago

$IKT accumulating @1.90

User Image penfly Posted - 1 week ago

$IKT so the news is delayed until maybe 2025?? Won't this price of 2.30 be a selling point for most people? Trial results could be negative and pushed back indefinitely..

Analyst Ratings
HC Wainwright & Co. Buy Aug 16, 24
HC Wainwright & Co. Buy May 21, 24
HC Wainwright & Co. Buy Mar 7, 24
HC Wainwright & Co. Buy Mar 5, 24
HC Wainwright & Co. Buy Aug 15, 23
HC Wainwright & Co. Buy Jun 30, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Werner Milton H. President and CEO President and CEO May 27 Buy 0.976 5,000 4,880 5,330,433 05/31/22
FRATTAROLI JOSEPH Chief Financial Offi.. Chief Financial Officer May 19 Buy 0.644 3,948 2,543 48,091 05/23/22